Arda Therapeutics
- 10/10/2024
- Series A
- $43,000,000
Arda is taking aim at chronic diseases and aging by eliminating the pathogenic cells that drive these conditions.
- Industry Biotechnology Research
- Website https://ardatx.com/
- LinkedIn https://www.linkedin.com/company/arda-therapeutics/
Related People
Adam FreundFounder
• Life sciences entrepreneur and executive with a Ph.D. in molecular and cell biology and 18 years of experience in research and drug development.
• Builds and leads teams with complex scientific objectives, listens actively, integrates diverse types of information to guide thoughtful decision making. Excels at developing program strategy, identifying and prioritizing key experiments, addressing rate limiting steps, gates, and critical path activities, and meeting deliverables and timelines.
• Substantial drug development experience across multiple therapeutic modalities including gene therapy, small molecule, large molecule, and cell therapy. Has led cross-functional teams through target discovery, target validation, mechanism of action investigation, indication selection, candidate selection, IND-enabling studies, and first-in-human study design.
• A strong record of building productive relationships with colleagues from multiple areas of expertise including biologists, biochemists, physiologists, clinicians, statisticians, machine learning engineers, business directors, lawyers, and executives.